Announcements Trials
Browse Landscape

Status

Not yet recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 73Observational 4Expanded_access 1

Sponsor

Cancer Type

Breast 4

Conditions

HER2-positive Breast Cancer 2Breast Neoplasms 2

Interventions

Surveys and Questionnaires 543Blood Specimen Collection 446Surgical Procedures, Operative 164Observation 152Drug Therapy 142Radiotherapy 141Interviews as Topic 139Gene Expression Profiling 129Biopsy 117Magnetic Resonance Spectroscopy 116Immunohistochemistry 112Data Collection 95Polymerase Chain Reaction 87Specimen Handling 81Amplified Fragment Length Polymorphism Analysis 81Bevacizumab 78Microarray Analysis 76Flow Cytometry 69Neoadjuvant Therapy 68Watchful Waiting 66Magnetic Resonance Imaging 65Immune Checkpoint Inhibitors 61Nivolumab 60Immunotherapy 57Therapeutics 55Reverse Transcriptase Polymerase Chain Reaction 52pembrolizumab 50Ultrasonography 47Positron Emission Tomography Computed Tomography 47Hematologic Tests 46

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Observational × neratinib × Clear all
NCT04388384 2025-08-06

ELEANOR

Pierre Fabre Pharma GmbH

Completed
304 enrolled
Breast

Breast Neoplasms

NCT07019272 2025-06-13

Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study

Hebei Medical University Fourth Hospital

Not yet recruiting
170 enrolled
Breast

HER2-positive Breast Cancer

NCT06693024 2024-11-20

NeraHER2

Peking University People's Hospital

Recruiting
2,806 enrolled
Breast

HER2-positive Breast Cancer

NCT05491057 2022-08-08

Treatment Patterns of Neratinib in HER2+ EBC in China

Pierre Fabre Medicament

Not yet recruiting
500 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡